MA40528A - Anticorps thérapeutiques qui se lient à oprf et oprl - Google Patents
Anticorps thérapeutiques qui se lient à oprf et oprlInfo
- Publication number
- MA40528A MA40528A MA040528A MA40528A MA40528A MA 40528 A MA40528 A MA 40528A MA 040528 A MA040528 A MA 040528A MA 40528 A MA40528 A MA 40528A MA 40528 A MA40528 A MA 40528A
- Authority
- MA
- Morocco
- Prior art keywords
- oprf
- opri
- antibody therapeutics
- bind
- oprl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1214—Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne des compositions et des méthodes se rapportant ou provenant d'anticorps anti-oprf et anti-oprl. Plus spécifiquement, cette invention concerne des anticorps entièrement humains qui se lient à oprf et oprl, à des fragments et des dérivés desdits anticorps se liant aux anticorps anti-oprf et anti-oprl, et des polypeptides se liant à oprf et oprl contenant lesdits fragments. L'invention concerne également des acides nucléiques codant pour ces anticorps, fragments et dérivés d'anticorps et
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462044107P | 2014-08-29 | 2014-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40528A true MA40528A (fr) | 2017-07-05 |
Family
ID=55400714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040528A MA40528A (fr) | 2014-08-29 | 2015-08-28 | Anticorps thérapeutiques qui se lient à oprf et oprl |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9879069B2 (fr) |
| EP (1) | EP3185897A4 (fr) |
| JP (1) | JP2017526686A (fr) |
| KR (1) | KR20170068456A (fr) |
| CN (1) | CN107073096A (fr) |
| AU (1) | AU2015308625A1 (fr) |
| BR (1) | BR112017003983A2 (fr) |
| CA (1) | CA2959165A1 (fr) |
| EA (1) | EA201790489A1 (fr) |
| IL (1) | IL250755A0 (fr) |
| MA (1) | MA40528A (fr) |
| MX (1) | MX2017002674A (fr) |
| PH (1) | PH12017500368A1 (fr) |
| SG (1) | SG11201701529YA (fr) |
| WO (1) | WO2016033547A1 (fr) |
| ZA (1) | ZA201701915B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11072652B2 (en) | 2016-03-10 | 2021-07-27 | Viela Bio, Inc. | ILT7 binding molecules and methods of using the same |
| US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
| WO2017163049A1 (fr) * | 2016-03-21 | 2017-09-28 | Kymab Limited | Anticorps anti-paludéens qui se lient à la protéine circumsporozoïte |
| US11485792B2 (en) | 2016-06-06 | 2022-11-01 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
| US12258378B2 (en) * | 2018-03-14 | 2025-03-25 | Dana-Farber Cancer Institute, Inc. | Engineered cells, T cell immune modulating antibodies and methods for using the same |
| WO2019192432A1 (fr) * | 2018-04-02 | 2019-10-10 | 上海博威生物医药有限公司 | Anticorps se liant au gène d'activation lymphocytaire 3 (lag-3) et son utilisation |
| FR3099160B1 (fr) | 2019-07-23 | 2022-05-06 | Univ Grenoble Alpes | Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE190657T1 (de) * | 1994-12-16 | 2000-04-15 | Chiron Behring Gmbh & Co | Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa |
| DK2356270T3 (da) * | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| CN103270047A (zh) * | 2010-12-23 | 2013-08-28 | 因特塞尔奥地利股份公司 | Oprf/i剂及其在住院患者和其他患者中的用途 |
| BR112013021411B1 (pt) * | 2011-02-23 | 2020-04-14 | Alzchem Ag | endurecedores de alta latência para resinas epóxi, seus usos, composição de resina epóxi e de poliuretano compreendendo os mesmos e material compósito |
| CN104736168B (zh) | 2012-05-31 | 2018-09-21 | 索伦托治疗有限公司 | 与pd-l1结合的抗原结合蛋白 |
-
2015
- 2015-08-28 CN CN201580058763.4A patent/CN107073096A/zh active Pending
- 2015-08-28 KR KR1020177008688A patent/KR20170068456A/ko not_active Withdrawn
- 2015-08-28 SG SG11201701529YA patent/SG11201701529YA/en unknown
- 2015-08-28 AU AU2015308625A patent/AU2015308625A1/en not_active Abandoned
- 2015-08-28 EA EA201790489A patent/EA201790489A1/ru unknown
- 2015-08-28 MA MA040528A patent/MA40528A/fr unknown
- 2015-08-28 US US14/839,791 patent/US9879069B2/en not_active Expired - Fee Related
- 2015-08-28 JP JP2017511769A patent/JP2017526686A/ja active Pending
- 2015-08-28 WO PCT/US2015/047576 patent/WO2016033547A1/fr not_active Ceased
- 2015-08-28 BR BR112017003983A patent/BR112017003983A2/pt not_active Application Discontinuation
- 2015-08-28 EP EP15836510.6A patent/EP3185897A4/fr not_active Withdrawn
- 2015-08-28 CA CA2959165A patent/CA2959165A1/fr not_active Abandoned
- 2015-08-28 MX MX2017002674A patent/MX2017002674A/es unknown
-
2017
- 2017-02-23 IL IL250755A patent/IL250755A0/en unknown
- 2017-02-28 PH PH12017500368A patent/PH12017500368A1/en unknown
- 2017-03-17 ZA ZA2017/01915A patent/ZA201701915B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107073096A (zh) | 2017-08-18 |
| CA2959165A1 (fr) | 2016-03-03 |
| PH12017500368A1 (en) | 2017-07-10 |
| US9879069B2 (en) | 2018-01-30 |
| EP3185897A1 (fr) | 2017-07-05 |
| IL250755A0 (en) | 2017-04-30 |
| EA201790489A1 (ru) | 2017-08-31 |
| BR112017003983A2 (pt) | 2018-02-14 |
| US20160060326A1 (en) | 2016-03-03 |
| KR20170068456A (ko) | 2017-06-19 |
| AU2015308625A1 (en) | 2017-04-20 |
| WO2016033547A1 (fr) | 2016-03-03 |
| JP2017526686A (ja) | 2017-09-14 |
| ZA201701915B (en) | 2018-05-30 |
| MX2017002674A (es) | 2017-09-19 |
| SG11201701529YA (en) | 2017-03-30 |
| WO2016033547A8 (fr) | 2017-04-06 |
| EP3185897A4 (fr) | 2018-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| MA40527A (fr) | Protéines de liaison à l'antigène se liant à wisp5 | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| MA40528A (fr) | Anticorps thérapeutiques qui se lient à oprf et oprl | |
| PH12017501077A1 (en) | Compositions and methods for antibodies targeting bmp6 | |
| MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| EP4249515A3 (fr) | Anticorps anti-cd3 humanisés ou chimériques | |
| PH12018500684A1 (en) | Agonistic antibodies specifically binding human cd40 and methods of use | |
| PH12017502180A1 (en) | Tau-binding antibodies | |
| PH12015502565A1 (en) | Anti-transferrin receptor antibodies and methods of use | |
| NZ728688A (en) | Anti-pd-1 antibodies | |
| MX2016014862A (es) | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. | |
| PH12018500906B1 (en) | Antibodies specifically binding pd-1 and their uses | |
| MY193723A (en) | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 | |
| PH12016501644B1 (en) | Binding proteins and methods of use thereof | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| MY193677A (en) | Tau-binding antibodies | |
| SG10201806454RA (en) | Anti-tenascin c antibodies and uses thereof | |
| MA40526A (fr) | Protéines de fixation antigénique fixant le cxcr3 | |
| MX2018011244A (es) | Anticuerpos monoclonales neutralizantes para il-25 y usos de estos. |